109082-85-1

Basic information

• Product Name: 6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]-
• Synonyms: 6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]-;N,O-Ditrityl Ganciclovir
• CAS NO: 109082-85-1
• Molecular Formula: C₄₇H₄₁N₅O₄
• Molecular Weight: 739.85954
• Mol File: 109082-85-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• Solubility: Chloroform, Ethyl Acetate, Methanol
• PKA: 9.27±0.20(Predicted)
• CAS DataBase Reference: 6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]-(CAS DataBase Reference)
• NIST Chemistry Reference: 6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]-(109082-85-1)
• EPA Substance Registry System: 6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]-(109082-85-1)

Safety Data

• Hazardous Substances Data: 109082-85-1(Hazardous Substances Data)

Usage

Description

6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]is a complex organic compound with a unique molecular structure. It is characterized by the presence of a 6H-purin-6-one core, which is a key component of many biologically active molecules. 6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]also features a 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]moiety, which contributes to its chemical properties and potential applications.

Uses

Used in Pharmaceutical Industry:
6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]is used as a pharmaceutical intermediate for the synthesis of various therapeutic agents. Its unique structure allows it to be modified and incorporated into a wide range of drug candidates, making it a valuable tool in the development of new medications.
Used in Research and Development:
6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]is also used in research and development settings, where it can be studied for its potential biological activities and interactions with other molecules. Its complex structure and diverse functional groups make it an interesting subject for scientific investigation, potentially leading to new discoveries and applications in various fields.
Used in Impurity Analysis:
6H-Purin-6-one, 1,9-dihydro-9-[[1-(hydroxyMethyl)-2-(triphenylMethoxy)ethoxy]Methyl]-2-[(triphenylMethyl)aMino]is used as an impurity in the analysis of Ganciclovir (G235000), a sugar-modified acyclic analogue of guanosine (G837900). Its presence as an impurity can help in understanding the purity and quality of Ganciclovir, ensuring the safety and efficacy of the drug.

Upstream product

• 82410-32-0 ganciclovir 
• 76-83-5 trityl chloride 

Downstream Products

• 109061-20-3 Adamantane-1-carboxylic acid 2-[6-oxo-2-(trityl-amino)-1,6-dihydro-purin-9-ylmethoxy]-3-trityloxy-propyl ester 
• 1219792-45-6 N,O-bistrityl-O-mesyl ganciclovir 
• 1219792-43-4 N-trytil-2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)methoxy-3-trityloxy-1'-propanyl-2'-(S)-azido-3'-methylbutanoate 
• 175865-59-5 valganciclovir hydrochloride 
• 88110-89-8 9-<(1-acetoxy-2-hydroxymethyl)ethoxymethyl>guanine 
• 1429306-17-1 C₄₉H₄₃N₅O₅ 
• 1429306-18-2 C₅₂H₄₉N₅O₅ 

Relevant articles and documents

Synthesis of valganciclovir hydrochloride congeners

Valganciclovir hydrochloride (1) is used for the treatment of cytomegalovirus (CMV) retinitis in patients with weakened immune systems. Valganciclovir hydrochloride is a hydrochloride salt of L-valyl ester of ganciclovir (2) that exists as a mixture of two diastereomers. According to the U.S. Food and Drug Administration specifications, the diastereomeric ratio of valganciclovir hydrochloride 1 should be maintained in the range 55:45 to 45:55. According to the U.S. Food and Drug Administration specifications, the diastereomeric ratio of valganciclovir hydrochloride 1 should be maintained in the range 55:45 to 45:55. During the process development of valganciclovir hydrochloride, six related substances (impurities) were observed along with the final active pharmaceutical ingredient. Among these six impurities, ganciclovir (2) and guanine (3) are the key starting materials and degraded impurities of ganciclovir, respectively. The remaining four impurities were identified as isovalganciclovir hydrochloride (4), methoxymethylguanine (5), O-acetoxy ganciclovir (6), and isovalarylganciclovir (7). The present work describes the synthesis and characterization of these four impurities.

PREPARATION OF VALGANCICLOVIR AND ITS SALTS

Processes for preparing valganciclovir and pharmaceutically acceptable salts thereof, as well as intermediates for the processes.

Synthesis and antiviral activity of various esters of 9-[1,3-dihydroxy-2-propoxy)methyl]guanine

-